SCM
ADCT icon

Saxony Capital Management’s ADC Therapeutics ADCT Stock Holding History

Saxony Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.4K Sell
23,768
-108
-0.5% -$315 0.01% 186
2026
Q1 		$89.5K Buy
23,876
+108
+0.5% +$426 0.05% 160
2025
Q4 		$83.9K Hold
23,768
– – 0.05% 160
2025
Q3 		$95.1K Hold
23,768
– – 0.06% 154
2025
Q2 		$63.7K Buy
23,768
+1,480
+7% +$3.11K 0.05% 127
2025
Q1 		$31.4K Hold
22,288
– – 0.03% 121
2024
Q4 		$44.4K Buy
22,288
+50
+0.2% +$131 0.04% 131
2024
Q3 		$70K Hold
22,238
– – 0.06% 134
2024
Q2 		$70.3K Buy
22,238
+1,615
+8% +$6.42K 0.08% 122
2024
Q1 		$92.6K Hold
20,623
– – 0.11% 111
2023
Q4 		$34.2K Buy
+20,623
New +$19K 0.05% 102

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Saxony Capital Management's ADCT Position: Q2 2026 in Review

Saxony Capital Management reduced its ADC Therapeutics (ADCT) stake by 0.45% in Q2 2026, selling an estimated $315 and leaving 23,768 shares worth $25.4K. The position accounts for 0.01% of the portfolio, ranked #186.

Saxony Capital Management first reported a position in ADCT in Q4 2023 and has held it in 11 quarters since. The position peaked at $95.1K in Q3 2025. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Saxony Capital Management held 23,768 shares of ADC Therapeutics worth $25.4K as of Q2 2026.
  • Saxony Capital Management sold 108 ADC Therapeutics shares in Q2 2026, an estimated $315.
  • ADC Therapeutics made up 0.01% of Saxony Capital Management's portfolio in Q2 2026, its #186 holding.
  • Saxony Capital Management first reported a position in ADC Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Saxony Capital Management's ADC Therapeutics position peaked at $95.1K in Q3 2025.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Saxony Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.